Revenue segments as reported by the company.

Immunology

Hematologic Oncology

Aesthetics

Neuroscience

Eye Care

Women's Health

Other Key Products

All other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Acquired in-process research and development

Other operating expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

AbbVie

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AbbVie surpasses Q4 earnings forecast, eyes growth amid challenges

AbbVie's strong performance in Q4 2022 exceeded expectations, driven by key products like SKYRIZI and RINVOQ. Despite challenges in revenue and HUMIRA erosion, the company is focused on innovation and growth opportunities. Strategic investments in R&D and BD aim to navigate market dynamics and drive future success.

AbbVie surpasses Q1 expectations, eyes international growth amid challenges

AbbVie's Q1 2023 performance exceeded expectations, driven by key product sales and strong international results. While facing challenges in the U.S. market and inflationary pressures, the company remains confident in its long-term growth prospects and strategic initiatives.

AbbVie surpasses Q2 expectations, eyes revenue growth opportunities

AbbVie's Q2 2023 earnings call highlighted strong financial performance, successful execution in key therapeutic areas, and a promising outlook for revenue growth. Despite challenges like biosimilar competition and market dynamics, the company remains confident in its ability to deliver value and maintain growth.

AbbVie exceeds Q3 expectations, focuses on pipeline growth strategies

AbbVie's strong Q3 performance driven by key products and growth platforms, with positive trial results.
Challenges in aesthetics sales and Medicare drug pricing program offset by long-term growth opportunities.
Confidence in pipeline assets and strategic focus on combination therapies for future growth.
Maintaining strong market positions and investing in transformative therapies for competitive advantage.

AbbVie exceeds Q4 expectations, eyes growth through strategic acquisitions

AbbVie's stellar performance in Q4 2023 showcased strong sales growth, successful pipeline advancements, and strategic acquisitions. While facing challenges such as pricing pressures and safety concerns, the company is well-positioned to capitalize on opportunities in expanding its portfolio and driving growth through innovation and strategic partnerships.

AbbVie exceeds Q1 expectations, raises full-year guidance on strong sales growth

AbbVie's Q1 performance exceeded expectations, with strong sales growth in key products. The company raised full-year guidance and remains confident in maintaining good access for its brands. Challenges in aesthetics sales and inventory management are being addressed for future growth.

AbbVie reports robust Q2 results and raises 2024 guidance

AbbVie's strong Q2 performance, raised guidance, and strategic acquisitions highlight its growth trajectory.
Despite near-term challenges, the company's focus on key growth areas positions it for long-term success.
Investments in innovation and market expansion underscore AbbVie's commitment to sustained growth.
Overall, AbbVie's performance in Q2 2024 reflects a resilient and forward-looking approach to business.

AbbVie reports strong Q3 performance, raises guidance and dividend

AbbVie's Q3 2024 performance showcased robust sales growth, increased dividend, and raised revenue guidance, reflecting financial strength and market leadership.
The company's focus on long-term sustainability through investments, acquisitions, and pipeline advancements highlights a commitment to innovation and growth.
While facing challenges in clinical trial management and market competition, AbbVie remains well-positioned to leverage opportunities in diverse therapeutic areas for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

This year isn't starting on the best of notes for the drugmaker.

With Competition on the Rise, Is AbbVie's Dividend Safe?

Biogen

Alphabet

UnitedHealth Group

The fountain of youth might not be a myth in the future.

This Monumental Breakthrough Could Turn the World Upside Down -- and Make Some Investors Filthy Rich

The stock offers an attractive yield, but investors need to brace for declining revenue this year.

Is AbbVie a Good Dividend Stock to Buy on the Dip?

American States Water

Kimberly-Clark

Lowe's

PPG Industries

Rely upon income-generating stocks to see your portfolio through times of upheaval.

5 Dividend Kings I Bought for My Portfolio

Caterpillar

CME Group

Canadian Pacific Kansas City Limited

Chevron

Deere & Company

Danaher

Duke Energy

Extra Space Storage

Huntington Bancshares

Home Depot

Huntington Ingalls Industries

L3Harris

Lockheed Martin

Nasdaq

Northrop Grumman

Norfolk Southern

PepsiCo

Public Storage

Raytheon Technologies

Schwab US Dividend Equity ETF

Union Pacific

Vanguard Dividend Appreciation ETF

Valero Energy

Vanguard High Dividend Yield ETF

As requested by many, I decided to dedicate an article to my personal dividend growth portfolio, consisting of more than 90% of my net worth. I start by explaining my strategy and approach, followed by a discussion of the benefits that come with dividend (growth) investment strategies.

My 6-Figure Market-Beating Dividend Growth Portfolio

Accenture Plc

Automatic Data Processing

Applied Materials

ASML Hld

Best Buy

Blackrock Inc

Cisco Systems

Expeditors International of Washington

Fastenal

Ferguson Enterprises Inc

Garmin

Infosys

KLA-Tencor

Lam Research

Mastercard

Monolithic Power Systems

Merck

Paychex

Rollins

Snap-on

Skyworks Solutions

The 4 factor dividend growth portfolio was launched on November 1st, 2022, and is thus far off to a great start. The portfolio generated 0.28% of alpha in December and continues to outpace the S&P 500 Total Return.

4 Factor Dividend Growth Portfolio - December 2022 Results

Amgen

BioNTech SE

CSL Ltd

Gilead Sciences

Horizon Pharma

Moderna

Pfizer

Repligen

Vertex Pharmaceuticals

The pipeline is the heart of all drug discovery companies, leading to all growth in the future. As such, understanding the relative strength of a pipeline by comparing to peers can lead to investment insights.

Ranking The 10 Largest Biotechs By Pipeline

One company is gearing up for further growth while the other stumbles over itself.

1 Hot Growth Stock to Buy Now, and 1 to Avoid

AbbVie Inc. (NYSE:ABBV ) 41st Annual J.P. Morgan Healthcare Conference Call January 10, 2023 6:00 PM ET Company Participants Rick Gonzalez - Chairman and Chief Executive Officer Rob Michael - President Jeff Stewart - Chief Commercial Officer Conference Call Participants Chris Schott - J.P.

AbbVie Inc. (ABBV) 41st Annual J.P. Morgan Healthcare Conference - (Transcript)

Innovative Industrial Properties

All three could make investors a little bit richer every quarter.

3 Passive Income Stocks That Are Screaming Buys in January

- Collaboration leverages Anima's mRNA Lightning technology platform and AbbVie's extensive expertise in Oncology and Immunology- Anima will receive an upfront payment of $42 million with potential for further milestones and royalties NORTH CHICAGO, Ill. and BERNARDSVILLE, N.J.

AbbVie and Anima Biotech Announce Collaboration for the Discovery and Development of mRNA Biology Modulators against Oncology and Immunology Targets

Air Products and Chemicals

SPDR S&P 500 ETF Trust

Travelers

Want to know how to invest in stocks? Check out a mutual fund that thrived in the past year, the toughest year since 2008, when the market fell 37%.

Fund Soars By Focusing On Income Stocks, Shunning Sector Bets

The risks are real, but they're decreasing over time.

Should Investors Worry About AbbVie's Dividend?

News for AbbVie Stock (ABBV)